Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Slides:

Advertisements

Similar presentations

Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in.

Advertisements

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Figure S3. in vivo Study of ABT-263 or SAR in the RS4;11 model in mice

Fig. 7. Role of PDE5 up-regulation in lung cancer–associated PH.

Fig. 5 Maraba induces antitumor T cell immunity.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 5. Prophylactic treatment with GS-5734 reduces SARS-CoV disease.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 8. In vivo suppression of MM by CMLD

Effects of SC144 on in vivo ovarian tumor.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 4 Infection-induced CLV dysfunction is associated with decreased LMC coverage. Infection-induced CLV dysfunction is associated with decreased LMC.

Intravenous delivery of reovirus to primary and secondary brain tumors

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 4. Specific versus nonspecific NP accumulation.

Fig. 8. Therapeutic effects of the transplantation of hiPSC-EPO–producing cells on renal anemia in adenine-treated mice. Therapeutic effects of the transplantation.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

SOM230 increases in vivo sensitivity to gemcitabine of tumour xenograft (MIA PaCa‐2‐Luc cells and CAFs or human PDAC resection) A–CMIA PaCa‐2‐GLuc cells.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Fig. 4 DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft tumor models. DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft.

Fig. 7. NPs accumulate at sites of vascular obstruction.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 7. Therapeutic effects of hiPSC-EPO protein on renal anemia in adenine-treated mice. Therapeutic effects of hiPSC-EPO protein on renal anemia in adenine-treated.

Fig. 8 SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and in vivo. SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and.

Fig. 1. PGBD5-expressing cells do not tolerate deficiency of nonhomologous end-joining DNA repair. PGBD5-expressing cells do not tolerate deficiency of.

Effects of in vivo Nutlin‐3 treatment on CSC content of Numb− and Numb+ tumors Effects of in vivo Nutlin‐3 treatment on CSC content of Numb− and Numb+

Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice

Fig. 6. pKL cells revert hyperglycemia in NOD mice in vivo.

Fig. 7. Treatment with DLK inhibitors reduces p-c-Jun and protects against neuronal and synaptic loss in vitro and in ALS mouse models. Treatment with.

Fig. 3. TKI sensitivity assessed by the MANO method.

Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.

Fig. 6 Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing mice. Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing.

Fig. 1 Collecting popliteal lymphatic vessels exhibit diminished contraction and lymph velocity after MRSA infection. Collecting popliteal lymphatic vessels.

Fig. 4. Dabrafenib and trametinib changed the cellular components of the tumor microenvironment. Dabrafenib and trametinib changed the cellular components.

Fig. 5. Prophylactic and therapeutic efficacy of C12G6 in ferrets.

The MEK inhibitor CI‐1040 reverses thickening, fibrosis, and angiogenesis in the parietal peritoneum of Cav1−/− mice upon exposure to PD fluidWT or Cav1−/−

Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts.

Fig. 5 Metarrestin treatment induces nucleolar structure changes.

Correlation of reovirus RNA/protein with proliferating tumor cells

Fig. 2. BET inhibition enhances PARPi-induced DNA damage.

Genetic EGFR ablation in K-RAS–mutated lung AC reduces tumor growth

E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective breast tumors. E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,

MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.

Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors by Anton G. Henssen, Casie Reed, Eileen Jiang, Heathcliff Dorado.

Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. Pharmacological targeting of CDs promotes response to KRASG12C inhibition.

Antitumor effects of celastrol in vitro and in vivo.

Targeting p53-dependent stem cell loss for intestinal chemoprotection

SY-1425 induces maturation in RARA-high AML

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

Effect of CDV on human SF7796 xenografts in vivo.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

Fig. 6 The combined therapeutic efficacy of N-pepABS and low dose of Dox on MDA-MB-231 xenografts. The combined therapeutic efficacy of N-pepABS and low.

Fig. 5 In vivo autologous self-targeting efficacy of DR-KO tumor cells co-engineered with a secretable DRL and a suicide system. In vivo autologous self-targeting.

GCS-100 selectively kills KRAS-addicted lung tumors.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Presentation transcript:

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. (A and B) Tumor volumes over time of nude mice harboring IMR5 (A) and HD-MB03 (B) subcutaneously xenografted tumors treated with AZD6738 by oral gavage at 50 mg/kg body weight per day (red) as compared to vehicle control (blue). *P < 0.05. Error bars represent SDs of 10 individual xenografted mice per group. Arrows denote start of treatment. (C) Representative photomicrographs of sections from IMR5 (top) or HD-MB03 (bottom) tumors upon completion of treatment with AZD6738 (50 mg/kg per day) or vehicle control in vivo, stained with hematoxylin and eosin (H&E) or for Ki67, ClCas3, or γH2AX, as indicated. (D to F) Quantification of the number of cells positively stained for Ki67 (D), ClCas3 (E), and γH2AX (F) in IMR5 or HD-MB03 xenograft tumors upon completion of treatment with AZD6738 (50 mg/kg per day; red) or vehicle control (blue) in vivo. *P = 3.1 × 10−5 and 0.0010 for Ki67 in AZD6738 versus vehicle-treated IMR5 and HD-MB03, respectively. *P = 0.014 and 4.3 × 10−4 for γH2AX in AZD6738 versus vehicle-treated IMR5 and HD-MB03, respectively. *P = 0.0010 and 4.9 × 10−4 for ClCas3 in AZD6738 versus vehicle-treated IMR5 and HD-MB03, respectively. Error bars represent SDs of three independent fields analyzed. Anton G. Henssen et al., Sci Transl Med 2017;9:eaam9078 Published by AAAS